PURE Bioscience (OTCMKTS:PURE) Short Interest Up 191.0% in June

PURE Bioscience (OTCMKTS:PURE) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 11,031 shares, an increase of 191.0% from the June 15th total of 3,791 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 30,287 shares, the short-interest ratio is currently 0.4 days.

PURE Bioscience Stock Performance

PURE Bioscience stock opened at $0.06 on Wednesday. PURE Bioscience has a 1 year low of $0.04 and a 1 year high of $0.14. The firm has a 50 day moving average price of $0.07 and a 200 day moving average price of $0.06. The company has a market cap of $8.23 million, a price-to-earnings ratio of -2.11 and a beta of 0.22.

PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings results on Monday, June 15th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.51 million for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.